Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of Moderna’s personalised cancer vaccine, intismeran autogene, and MSD’s stalwart oncology drug, Keytruda (pembrolizumab), has significantly extended recurrence-free …
Post
-
-
Innovations in Dermatology Trials: Embracing Digital Tools and Decentralized Approaches
Skin disease has a growing profile in drug development. New immuno-dermatology agents, topical biologics and cell-based treatments are moving through …
-
Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial
Tanabe Pharma America’s oral melanocortin-1 receptor (MC1R) agonist has met the primary endpoint in a Phase III trial in patients …
-
Meta-analysis confirms nephroprotective benefits of ERAs
A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of …
-
UK DRI announces trial of blood test for Alzheimer’s diagnosis
The UK Dementia Research Institute (DRI) has announced an international research study, which is underway to assess whether a finger-prick …
-
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
D3 Bio has received the US Food and Drug Administration (FDA) clearance for two investigational new drug (IND) applications, enabling …
-
2026: The time for AI to really deliver
In 2026, clinical trial design will be reshaped by artificial intelligence (AI)-powered simulation and richer clinical and real-world data. Improvements …
-
Nxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50mg, aimed at treating insomnia in …
-
JPM26: Immunocore Signals Entry into Type 1 Diabetes
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities …
-
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its …
-
Clinical Trials Arena Excellence Awards 2025: Incannex Healthcare
Incannex Healthcare (Nasdaq: IXHL), a clinical‑stage pharmaceutical development company focused on developing novel therapies for conditions with limited effective treatment …
-
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK) showed over 15 …
-
OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy
OrsoBio has announced the publication in Nature Medicine of Phase I clinical trial data for TLC-2716, an oral liver-targeted inverse …
-
Genmab reports top line results in Phase III DLBCL trial
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival …
-
Speech biomarkers offer new lease of life to patient experience and trial retention
Biomarkers remain a critical measurement in almost every clinical trial, with this type of data facilitating the accurate characterisation of …
